Aims: Statins can ameliorate atherosclerosis by inhibition of cholesterol biosynthesis or by modulation of inflammation. In earlier work, we showed that homocysteine (Hcy) reduced synthesis of apolipoprotein A-I (ApoA-I). Our goal in this study was to determine whether Hcy could interfere with the ability of simvastatin to increase ApoA-I synthesis or to modify statindependent regulation of inflammatory factors. Methods: Human HepG2 hepatocarcinoma cells and murine RAW264.7 macrophages were treated with simvastatin, with and without homocysteine, to examine expression of ApoA-I and nuclear factor-κB (NF-κB) or the NF-κB target, inducible nitric oxide synthase (iNOS), respectively. Mice with methylenetetrahydrofolate reductase (Mthfr) deficiency, an animal model of hyperhomocysteinemia, were administered simvastatin (in diets or by injection) for in vivo assessment of these interactions. Results: In HepG2 cells, Hcy reduced the statin-dependent increases in ApoA-I protein, mRNA and ApoA-I promoter activity. In RAW264.7 macrophages, simvastatin decreased, whereas Hcy increased, the expression of pro-inflammatory NF-κB protein; in the presence of both Hcy and simvastatin, the pro-inflammatory effect of Hcy prevailed. Hcy increased mRNA levels of iNOS in the macrophage line; the combination of Hcy and simvastatin resulted in a trend towards greater induction. In mouse studies, simvastatin decreased cholesterol levels but levels of ApoA-I in 
Introduction
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are the first-line therapy in the treatment of cholesterol-induced cardiovascular disease (CVD).
1 They inhibit endogenous cholesterol synthesis by blocking the rate-limiting step and are highly effective in reducing levels of low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL).
Statins are also modestly effective in raising levels of high-density lipoprotein (HDL) and lowering triglycerides. 2, 3 Recent findings indicate that, in addition to modulating plasma lipids, statins exert pleiotropic anti-inflammatory effects which might contribute to their therapeutic role in CVD 4 . The protective effects of statins on the vascular system include improvement of endothelial function, stabilization of fibrous plaques, decreased vascular inflammation, and reduction of C-reactive protein. 5 In the cerebral circulation, statins up-regulate endothelial nitric oxide synthase (eNOS) and inhibit inducible nitric oxide synthase (iNOS), actions that may have neuroprotective potential. 6 Increased plasma homocysteine (Hcy) levels have become widely accepted as an independent risk factor for vascular disease. 7, 8 Hyperhomocysteinemia (HHcy), a condition that arises from disrupted Hcy metabolism, is caused by genetic and dietary deficiencies and has been implicated in the pathophysiology of atherosclerosis. A polymorphism (677C→T) in the enzyme methylenetetrahydrofolate reductase (MTHFR) is the most common genetic cause of mild HHcy. 9 In a previous study, we showed that HHcy is associated with decreased Apolipoprotein A-I (ApoA-I) expression in humans and hyperhomocysteinemic Mthfr-deficient mice. We suggested that HHcy could increase the risk of atherosclerosis by decreasing ApoA-I through modulation of peroxisome-proliferator activated receptor alpha (PPARα). 10 The literature is mixed regarding the use of mice as an animal model to study the lipid-lowering effect of statins. 11 Some studies have
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reported a decrease in ApoA-I levels following statin treatment in rodents, whereas others have seen an increase or no effect. [12] [13] [14] Atherosclerosis is characterized by infiltration of monocytes into the arterial wall. The monocytes differentiate into macrophages and subsequently produce factors that promote atherosclerosis. 15 One factor is nitric oxide (NO), which is regulated by one of three isoforms of NO synthase: eNOS, iNOS, and neuronal NOS (nNOS). eNOS-derived NO, at low concentrations, may modulate vasodilation and act as a hemodynamic regulator. 16 iNOS, expressed mainly in macrophages, is responsible for the release of high NO levels. Excessive NO production due to elevated iNOS may exert cytotoxic effects on vascular cells. The iNOS gene promoter contains multiple cytokine-responsive elements including several NF-κB binding sites 17 and its expression is controlled by the activation of NF-κB. 16 Homocysteine is known to activate NFκB via oxidative stress in endothelial cells 18 and potentially through protein kinase C (PKC) in smooth muscle cells. 15 iNOS expression in vascular smooth muscle cells is believed to promote atherosclerosis by increasing local oxidative stress. In rat aortic smooth muscle cells, Hcy treatment was shown to increase iNOS mRNA, activate NF-κB and potentiate NF-κB cytokine activation. 19 In human endothelial and vascular smooth muscle cells, HMG-CoA reductase inhibitors down-regulate the activation of NF-κB and activator protein-1 (AP-1), 20 and in rabbit peripheral blood mononuclear cells (PBMCs), simvastatin is also believed to reduce NF-κB activity. 21 In murine RAW264.7 macrophages, statins inhibit expression of lipopolysaccharide-(LPS) induced iNOS 22 and up-regulate heme-oxygenase-1 expression. 23 However, the iNOS-blocking effect of statins is cell-type dependent. 24 In the present study, we tested the effect of simvastatin in vivo in Mthfr-deficient mice, a well-characterized animal model for mild hyperhomocysteinemia and MTHFR deficiency in 

Methods
Materials
Cell culture
Human HepG2 hepatocarcinoma cells and murine RAW264.7 macrophages were propagated at 37°C in 5% CO 2 in DMEM-F12, and DMEM, respectively, containing 10% FBS, 100 µg/ml penicillin and streptomycin. For transfections and experiments involving treatment with compounds, cells were cultured in 24-well or 6-well plates.
Transient transfection studies
HepG2 cells were seeded at approximately 2.5 X 10 5 into 24-well plates and medium was changed regularly. At 90% confluence, cells were transfected with a human ApoA-I promoter construct either wild-type or mutated in the PPARα response element (PPRE) that had been generated previously. were controlled by normalizing to β-galactosidase activity (AP-Biosystems) as previously described. 10 Transfections were performed at least four times.
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Western blotting
Cell lysates and mouse liver extracts were prepared and processed for electrophoresis and immunoblotting as described previously. 10 Primary antibodies were anti-human ApoA-I (Calbiochem), anti-mouse ApoA-I (Biodesign International), anti-β-actin (Sigma), anti-albumin (Bethyl Laboratories), anti-NF-κBp65 (Santa Cruz Biotechnology), anti-iNOS (BD Biosciences) and anti-MTHFR. 9 All primary antibodies were made in rabbit. Secondary antibody was peroxidase-coupled anti-rabbit IgG (Amersham). Signal detection was achieved with ECL Plus chemiluminescence system (Amersham) and exposure to X-ray films. Signals were quantified relative to control with Quantity One 4.1.0 software.
Quantitative real-time reverse transcription-PCR
RNA was isolated from liver, HepG2, RAW264.7 cells and PBMC using RNeasy Mini kit (Qiagen) following the manufacturer's protocols. RNA was DNaseI-treated and reversetranscribed using random primers. Real-time PCR was performed with the SyberGreen kit in Mx4000P QPCRsystem (Stratagene) or Biometra thermocycler. Primers for amplifying mouse and human ApoA-I, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), MTHFR, iNOS and NF-κB are listed in Table 1 . Samples were run in duplicate and analysis of RT-PCR data was performed by normalizing against GAPDH.
Statistical analysis
ANOVA and t-tests were used for statistical analyses with SPSS software. One-sample t-tests were used for comparison with untreated cells, and independent-sample t-tests were used to compare between treatments. P<0.05 was considered significant.
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Results
Effect of simvastatin and Hcy on ApoA-I and MTHFR protein levels in HepG2 cells
In previous work, we showed that Hcy decreased ApoA-I expression in HepG2 cells. Methionine at the same concentration as Hcy did not affect simvastatin-dependent induction of ApoA-I (data not shown), consistent with a lack of effect of methionine alone on ApoA-I levels in our earlier report.
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We also examined the potential impact of simvastatin on MTHFR expression. MTHFR has two protein isoforms, 70-and 77-kDa, differing in the length of their coding sequence. The shorter 70-kDa isoform can be post-translationally modified by phosphorylation and therefore exists as phosphorylated (P-MTHFR) and non-phosphorylated (non-P-MTHFR) species. In HepG2 cells, only the 70-kDa isoform is present but can be observed as both P-MTHFR and non-P-MTHFR.
Compared with untreated cells, treatment with Hcy significantly induced expression of non-P-MTHFR whereas simvastatin induced P-MTHFR 2.4-fold ( Figure 1A and 1C) . In the presence of Accepted Manuscript both simvastatin and Hcy, the effect of Hcy was predominant, i.e. reduced levels of P-MTHFR (p<0.05) compared to simvastatin treatment alone ( Figure 1A , lanes 4-6).
Quantitative RT-PCR confirmed the effects of Hcy and simvastatin on ApoA-I mRNA expression, but no change was observed for MTHFR mRNA. Compared to untreated cells, Hcy reduced ApoA-I mRNA by 30%, simvastatin induced it by 40%, and in the presence of both compounds, ApoA-I reduction was 43% compared to simvastatin treatment alone and 20% lower compared to untreated cells (data not shown).
Effect of simvastatin and Hcy on ApoA-I promoter activity in HepG2 cells
To While 1 mmol/L Hcy had no effect alone, it was still able to significantly reverse simvastatin- was observed between total plasma Hcy and ApoA-I levels in mice on both diets. We previously observed a similar correlation in BALB/c mice.
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Liver MTHFR protein levels were also analyzed in the afore-mentioned experiments. Figure   3A shows both the phosphorylated (P-MTHFR) and non-phosphorylated (non-P-MTHFR) forms of the 70-kDa MTHFR isoform from Mthfr +/+ mice on control (lanes 1-2) and simvastatin (lanes 3-4) diets. Mthfr +/-mice had lower MTHFR levels, as expected, in both dietary groups ( Figure 3B, p<0.001). Simvastatin increased MTHFR levels (p<0.01), predominantly the phosphorylated Accepted Manuscript isoform ( Figure 3A) ; this pattern was similar to that observed for MTHFR in HepG2 cells ( Figure   1A ). Simvastatin did not alter Mthfr mRNA levels (data not shown).
Effect of simvastatin and Hcy on NF-κB p65, MTHFR and iNOS in RAW264.7 cells
To determine whether Hcy could interfere with some of the anti-inflammatory activities of simvastatin, we measured protein levels of the NF-κB p65 subunit, since Hcy can increase NF-κB activity 15, 18 and statins decrease expression of iNOS, a down-stream effector of NF-κB, in some cell types. 22 In murine RAW264.7 macrophages treated with simvastatin ( Figure 4A ), there was a ~25% reduction in NF-κB p65 (p<0.05) after 8 hours, compared to untreated cells. Hcy treatment increased NF-κB p65 levels 1.5-fold (p<0.05) compared to untreated cells. In the presence of both simvastatin and Hcy, there was a 2-fold increase in NF-κB p65 compared to simvastatin alone (p<0.05) and no change compared to Hcy alone. This increase was not observed for NF-κB p65 
Effect of simvastatin on iNOS in PBMCs of Mthfr-deficient mice
To examine the possible interaction between simvastatin and Hcy in the inflammatory response in vivo, we isolated mice PBMCs after an injection of simvastatin at a dose known to elicit an anti-inflammatory response. 27 Because NF-κB could not be detected in these PBMCs, we measured iNOS again as a downstream effector of NF-κB. There were no differences in iNOS expression due to genotype in the control group ( Figure 5A and 5B). However, simvastatin significantly increased iNOS levels in PBMCs (p<0.001 for treatment, ANOVA). Since the ANOVA indicated that there was an interaction between simvastatin and genotype (p<0.05), we performed t tests which revealed that this treatment effect was significant only for the Mthfr 
Hcy inhibition of simvastatin-induced ApoA-I production in vitro
Several mechanisms have been proposed by which elevated levels of Hcy can lead to atherosclerosis including direct effects on lipid metabolism and transport, protein modification, oxidative stress and/or endoplasmic reticulum stress. 28 We explored another mechanism and demonstrated that HHcy reduced the expression of ApoA-I in men with coronary artery disease,
Mthfr-deficient mice and HepG2 cells. 10 In this study, we show that simvastatin induces ApoA-I protein and mRNA, as well as ApoA-I promoter activity in HepG2 cells; these observations are consistent with earlier studies in HepG2 cells and hamster hepatocytes. 29, 30 However, Hcy inhibits the statin-dependent increases in ApoA-I protein, mRNA and promoter activity in HepG2 cells.
Another group has confirmed our initial findings on Hcy regulation of ApoA-I protein levels, although, in contrast to our results, they did not observe changes in ApoA-I mRNA levels. 31 In the promoter studies, Hcy at concentrations of both 1 and 5 mmol/L antagonized the effect of simvastatin on the wild-type ApoA-I promoter and a promoter that was mutated at a PPRE site. Statins can upregulate "A-site" activity of the human ApoA-I promoter through activation of PPARα. 29 Our data are consistent with this finding but they also allude to activity in the promoter region independent of the PPRE site since simvastatin was able to enhance activity in the mutant as well as wild-type promoters.
Simvastatin effects in vivo
Levels of total and HDL-cholesterol and ApoA-I protein decreased in plasma and liver of mice following treatment with simvastatin-containing diets in all 3 MTHFR genotype groups.
studies. [12] [13] [14] The statin-dependent decrease in HDL in mice is distinct from the statin effects on HDL in human populations. In this study, we observed a statin-dependent increase in human
ApoA-I promoter activity in HepG2 cells. Whether statin has the same effect on the murine ApoA-I promoter remains to be determined.
Despite the differences in statin action between mice and humans, MTHFR deficiency in our mice was associated with reduced plasma and liver ApoA-I levels, and reduced HDLcholesterol and total cholesterol, in mice on control and statin-containing diets. Since we and others 10, 31 have demonstrated that HHcy in humans is also associated with decreased ApoA-I levels, it is possible that statins may not be able to completely reverse the Hcy-induced ApoA-I decrease.
Simvastatin treatment of mice did not significantly affect plasma Hcy levels; this observation has been reported in some but not all clinical reports on statins. 32, 33 Ridker et al 33 reported that both lovastatin and placebo were associated with homocysteine lowering. Statins also reduced the recurrence of coronary events in individuals with high homocysteine, suggesting that hyperhomocysteinemia did not interfere with statin action. Our findings in mice are consistent with this observation, since statins effectively reduced cholesterol in all groups of mice, yet the differences between genotypes in HDL-cholesterol were still evident. In a smaller study that reported a reduction in Hcy after simvastatin therapy, decreased Hcy was not associated with a reduction in total cholesterol, triglycerides, LDL and ApoB. 34 In addition to the afore-mentioned types of studies that are centered on statin therapy, it would be useful to examine the interaction between Hcy and statin in the clinical trials that are currently underway to target Hcy lowering.
Simvastatin may exert some of its pleiotropic effects indirectly through an increase in MTHFR expression, which regulates Hcy levels, as observed in HepG2 cells and mouse liver.
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Although simvastatin increased MTHFR levels in liver, plasma Hcy was not influenced by simvastatin. This finding could be due to the fact that plasma levels reflect export of Hcy from many tissues. Nonetheless, it is possible that there are tissue-specific changes in Hcy or related metabolites, due to the drug's effect on MTHFR. MTHFR is also required for generation of Sadenosylmethionine which is utilized as a carbon donor in a wide variety of methylation reactions.
We have recently suggested that MTHFR may be important in cell survival, since it is upregulated during endoplasmic reticulum stress. 26 The intriguing connection between simvastatin and MTHFR warrants further investigation, particularly in individuals with the MTHFR polymorphism.
Hcy interference with anti-inflammatory properties of simvastatin
During the onset of atherosclerosis, NF-κB activation is associated with increased expression of inflammatory factors. 18 Active NF-κB binds to κB-binding motifs in the promoters of several immunomodulator genes including iNOS. In RAW264.7 macrophages, expression of the p65 subunit of NF-κB decreased in response to simvastatin and increased in response to Hcy.
In the presence of both compounds, NF-κB p65 levels were 2-fold higher compared to simvastatin treatment alone demonstrating that Hcy may counteract the effect of simvastatin. We also observed that Hcy induced mRNA levels of iNOS, and that simvastatin was unable to reverse this induction. To investigate the potential interaction between HHcy and statins in the inflammatory pathway in vivo, we examined a short-term exposure to simvastatin in wild-type and hyperhomocysteinemic mice. The increase in iNOS protein and mRNA in hyperhomocysteinemic mice following statin treatment, but not in normohomocysteinemic mice, provides evidence for an interaction.
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The iNOS-modulating effect of statins is dependent on the cell type and on the specific statin. Statins can reduce LPS-induced iNOS production and NF-κB activation in RAW264.7 macrophages depending on the level of their hydrophobicity. 22 Lovastatin inhibits iNOS expression in rat macrophages 35 whereas atorvastatin up-regulates iNOS expression in vascular smooth muscle cells. In rat aortic vascular smooth muscle cells, atorvastatin up-regulates iNOS expression and activity resulting in increased NO production, but this induction is not NF-κB-dependent. 36 Interesting to note that in this same cell line, Hcy was shown to induce iNOS expression and NO production via NF-κB activation. 19 Our results are consistent with this finding since Hcy increased expression of the NF-κB p65 subunit and of iNOS in RAW264.7
macrophages. The increase in iNOS levels in PBMCs of Mthfr +/-mice in response to simvastatin is consistent with our in vitro data and suggests that simvastatin may have different effects on the inflammatory response depending on the levels of Hcy. The molecular mechanisms by which statins and homocysteine interact in the inflammatory cascade require dissection, particularly since atherosclerosis is associated with chronic inflammation.
Peritoneal macrophages cultured from PPARα +/+ mice injected with simvastatin respond in vitro by a reduction of LPS-induced iNOS, whereas PPARα -/-mice do not respond, suggesting that simvastatin activity is through a PPAR site. 27 Our in vitro and in vivo data suggest that the effect of Hcy and simvastatin on iNOS was greater than either compound alone. Whether these effects on iNOS occur through Hcy-and statin-dependent modulaton of PPARα remain to be determined.
We have nonetheless reported a putative PPRE in the sequence upstream of the Mthfr promoter and shown that PPARα up-regulates MTHFR.
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Limitations of the study
In order to increase intracellular Hcy levels in cultured cells, 5 mmol/L Hcy is required in vitro. 10, 26, 37 Although supraphysiological, this concentration is necessary to attain a transient increase in intracellular Hcy and does not affect cell viability. 37 We used DL-homocysteine in our experiments, which is only 50% biologically active in cells, thereby necessitating higher concentrations of the compound. Nonetheless, in the promoter studies, Hcy at a concentration of 1 mmol/L was effective in inhibiting simvastatin-induced ApoA-I promoter activity. Furthermore, some of the interactions between statin and Hcy metabolism were reproduced in vivo. The interaction between Hcy and simvastatin on iNOS in RAW264.7 macrophages ( Figure 4B ) was also detected in mouse PBMCs where simvastatin increased iNOS protein ( Figure 5 ) in Mthfrdeficient mice that have a modest elevation in plasma Hcy.
Conclusions
We suggest that Hcy may influence the anti-atherogenic properties of simvastatin through Accepted Manuscript Accepted Manuscript 
